O
Ovid Therapeutics Inc. (OVID)
NCM – Real vaqt narxi. Valyuta: USD
2.30
-0.16 (-6.50%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.25
-0.05 (-2.17%)
Bozordan keyin: Mar 27, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
2.30
-0.16 (-6.50%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.25
-0.05 (-2.17%)
Bozordan keyin: Mar 27, 2026, 7:59 PM EDT
Ovid Therapeutics Inc., biotexnologiya kompaniyasi, AQShda epilepsiya va tirishish bilan bog'liq nevrologik kasalliklar, shu jumladan miya kasalliklari uchun kichik molekulali dori vositalarini ishlab chiqish bilan shug'ullanadi. Kompaniya OV329, GABAA-AT inhibitorni ishlab chiqmoqda, u kattalar va chaqaloqlardagi dori-darmonga chidamli epilepsiyani davolash uchun 1-bosqich klinik sinovlarida; va OV4071, Parkinson kasalligi, Lewy tana demansiyasi va o'tkir shizofreniya bilan bog'liq psixozni davolash uchun 1-bosqich klinik sinovlarida bo'lgan birinchi inson og'zaki kaliy-xlorid kotransporter 2 to'g'ridan-to'g'ri faollashtiruvchisi. Kompaniya AstraZeneca AB, H. Lundbeck A/S, Shimoli-g'arbiy universitet va Graviton, shuningdek Marinus Pharmaceuticals, Inc. bilan litsenziya va hamkorlik shartnomalariga ega. Kompaniya 2014 yilda tashkil etilgan va shtab-kvartirasi Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Co-Founder & Executive Chairman |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research |
| Dr. Zhong Zhong Ph.D. | Chief Scientific Officer |
| Mr. Charles Ross Carter | Senior VP of Finance & Financial Planning |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-18 | S-8 | ovids-82026x03x17.htm |
| 2025-12-18 | 8-K | d84904d8k.htm |
| 2025-12-15 | S-3 | d35579ds3.htm |
| 2025-12-11 | 8-K | ovid-20251211.htm |
| 2025-11-12 | 10-Q | ovid-20250930.htm |
| 2025-11-07 | DEF 14A | ny20057375x3_def14a.htm |
| 2025-10-28 | PRE 14A | ny20057375x2_pre14a.htm |
| 2025-10-27 | PREM14A | ny20057375x1_pre14a.htm |
| 2025-10-03 | 8-K | d45212d8k.htm |
| 2025-09-16 | 8-K | d80889d8k.htm |
| Mr. Jeffrey A. Rona | Chief Business & Financial Officer and Corporate Secretary |
| Mr. Tom Parry | Vice President of Research and Early Development |
| Ms. Victoria Fort | Senior Vice President of Corporate Affairs & Corporate Strategy |